title: [Primay hyperaldosteronism--diagnostic and treatment].
abstract: Primary hyperaldosteronism (PHA) is characterized by an increased Aldosterone synthesis which is independent of the Renin-Angiotensin-Aldosterone-System (RAAS). The prevalence of PHA in patients who present in specialized hypertension centers is approx. 10 %. Besides patients with the classical symptoms known as "Conn-Trias" (hypertension, hypokalemia, metabolic alkalosis), the more frequent normokalemic patients with PHA also show a worse outcome compared to patients with essential hypertension. Identifying these patients is an important task in the evaluation of hypertension since targeted treatment options are available. Screening for PHA using the Aldosterone-Renin-Ratio (ARR) should be performed in patients with hypokalemic, severe or resistant hypertension. In addition, young patients with early onset of severe hypertension and/or positive family history should be screened. A positive screening result should be followed by a confirmatory test. The saline infusion test is the preferred clinical test for confirming a suspected PHA since it is accessible and time efficient. Other confirmatory tests are not used on a regular basis. After any confirmatory test, CT- or MRI-imaging and adrenal vein sampling (AVS) is used in order to differentiate between a unilateral adenoma, a bilateral hyperplasia or another cause of PHA. CT or MRI usually cannot discriminate smaller tumors form hyperplasia. Therefore AVS is used to detect lateralization of autonomous aldosterone production. Lateralization of aldosterone production indicates a unilateral adenoma. In these cases, laparoscopic adrenalectomy is the therapeutic option of choice with a hypertension cure rate of up to 60 %. If no lateralization is detectable, bilateral hyperplasia as the underlying cause of PHA is likely. Pharmacological inhibition of the mineralocorticoid receptor is the preferred treatment option in these cases. If Spironolactone is not well tolerated, Eplerenone and potassium-sparing diuretics should be prescribed. Often, however, in order to fully control hypertension, additional antihypertensive therapy is necessary.
authors.affiliation: Universität Düsseldorf, Medizinische Fakultät, Universitätsklinikum Düsseldorf, Klinik für Nephrologie, Düsseldorf, Germany. sebastian.potthoff@med.uni-duesseldorf.de
authors.forename: S A
authors.initials: SA
authors.lastname: Potthoff
authors.forename: F
authors.initials: F
authors.lastname: Beuschlein
authors.forename: O
authors.initials: O
authors.lastname: Vonend
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000097:blood / Q000175:diagnosis / Q000628:therapy; D000311:Adrenal Glands / Q000473:pathology; D000312:Adrenal Hyperplasia, Congenital / Q000097:blood / Q000175:diagnosis / Q000628:therapy; D018246:Adrenocortical Adenoma / Q000097:blood / Q000175:diagnosis / Q000628:therapy; D000450:Aldosterone / Q000097:blood; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D000077545:Eplerenone; D006929:Hyperaldosteronism / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D006973:Hypertension / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D007008:Hypokalemia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008403:Mass Screening; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000031:analogs & derivatives / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
chemical_list: D000959:Antihypertensive Agents; D013148:Spironolactone; D000450:Aldosterone; D000077545:Eplerenone; D012083:Renin